Navigation Links
Index Ventures Closes Euro 350 Million Early Stage Fund
Date:3/2/2009

Ben Holmes Named Partner

LONDON, March 3 /PRNewswire/ -- Index Ventures today announced the closing of a euro 350 million early stage fund, Index Ventures V. The fund is dedicated to early stage and seed investments in the technology, biotechnology and clean technology sectors across Europe, the United States and Israel. It is the fifth early stage fund Index has raised in the past ten years and reinforces the firm's commitment to investing in innovative and disruptive companies, from the very earliest stages. The fund was raised almost entirely from the firm's existing base of limited partners.

"Over the past twelve years, we have been fortunate enough to work with some of the most successful entrepreneurs in the world who have started game-changing companies such as Betfair, Skype, MySQL and GenMab," said partner Bernard Dalle. "There are certainly challenges facing many industries right now but, thanks to the ongoing commitment of our limited partners, we can continue to focus on our core strength, that of finding and supporting ambitious, dedicated entrepreneurs."

Operating from offices in Geneva, London and Jersey, Index invests in companies across multiple geographies. Investments made during the last twelve months include: Criteo (France), DimDim (India), Lehigh Technologies (US), MyHeritage (Israel), NormOxys (France), OpTier (Israel), Playfish (UK), RightScale (US), and WooMe (UK/US).

Francesco De Rubertis, Index partner, added, "On the biotech side, Index is focused on finding the best companies with the strongest pipelines. We are equally interested in very early stage ventures and more mature companies with established proof-of-concept. In terms of therapeutic areas, our priorities are oncology, CNS, immunology and inflammation. We continue to see tremendous innovation and development within these areas, driven in part by the ever growing pharmaceutical pipeline deficit."

Index also announced today that Ben Holmes, a London-based member of the technology team since 2002, has been named a partner of the firm. Ben focuses on investments in consumer and internet infrastructure companies and currently sits on a number of boards including Mind Candy, Netlog, Playfish, Rebtel and Stardoll.

"Since joining our London office in 2002, Ben has played a key role in sourcing and supporting investments we have made in internet and software sectors," said Danny Rimer, partner at Index Ventures. "We are excited to announce his promotion and we look forward to his ongoing contributions to the firm and our portfolio companies."

In addition, Tony Zappala and Roman Fleck, both based in the firm's Geneva office, have been promoted to principals in the IT and biotech teams respectively.

About Index

Index Ventures is a leading venture capital firm active in venture investing since 1996. For more information, please visit www.indexventures.com


'/>"/>
SOURCE Index Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Names New Senior Science Officer; Added to S&P Index
2. NASDAQ OMX AeA Illinois Tech Index Outperforms Market
3. Micromet Added to NASDAQ Biotechnology Index
4. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
5. Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences
6. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
7. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
8. Advanced Life Sciences Added to Russell Microcap Index
9. Bioheart, Inc., Added to Russell Microcap Index
10. Pharmasset Joins Russell 3000 Index
11. Caliper Life Sciences Added to Russell 3000(R) Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... , March 23, 2017 ... at four equities in the Biotech industry: Sangamo Therapeutics ... Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. ... st , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology ... downloading their free report at: ...
Breaking Biology Technology:
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):